Use of cytarabine and idarubicin in a newly diagnosed AML patient with a severe wound
| dc.contributor.author | Bozoglan H. | |
| dc.contributor.author | Ergene U. | |
| dc.contributor.author | Yoleri L. | |
| dc.date.accessioned | 2025-04-10T11:15:13Z | |
| dc.date.available | 2025-04-10T11:15:13Z | |
| dc.date.issued | 2011 | |
| dc.description.abstract | Acute myeloid leukemia (AML) is malignant tumor of haemopoietic precursor cells of non-lymphoid lineage. AML can atypically present with non-spesific cutaneous lesions or wounds. There are rare acute leukemia cases which present with genital ulcerations or pyoderma gangrenosum in the literature. The effect of acute leukemia on wound healing is not known, but it is thought that cytopenias and chemotherapy can impair wound healing in patients with leukemia. The effects of chemotherapeutic agents on wound healing are arguable. Here we present wound care strategies and simultaneously applied chemotherapy in an AML patient. © 2011 Elsevier Ltd. | |
| dc.identifier.DOI-ID | 10.1016/j.transci.2011.06.016 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14701/50830 | |
| dc.title | Use of cytarabine and idarubicin in a newly diagnosed AML patient with a severe wound | |
| dc.type | Article |